Recombinant bactericidal/permeability-increasing protein (rBPI21) for treatment of parvovirus enteritis: A randomized, double-blinded, placebo-controlled trial

Journal of Veterinary Internal Medicine

Volumn 15, Issue 4, 2001, Pages 355-360

  Otto, Cynthia M ^a,d   Jackson, C Bisque ^a   Rogell, Emily J ^a   Prior, Richard B ^b   Ammons, W Steve ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c XOMA Corporation   (United States)

^d Dept of Clin Studies Philadelphia ^*  (United States)

Author keywords

Clinical trial; Endotoxin; Puppies; Viral enteritis

Indexed keywords

ENDOTOXIN; ENDOTOXIN BINDING PROTEINS; MEMBRANE PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; ENTERITIS; ISOLATION AND PURIFICATION; MORTALITY; PARVOVIRUS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; VIRUS INFECTION;

ANIMALS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; ENDOTOXINS; ENTERITIS; MEMBRANE PROTEINS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS, CANINE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035409425     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2001.tb02329.x     Document Type: Article

References (15)

1. Smith-Carr S, Macintire DK, Swango LJ. Canine parvovirus. Part I. Pathogenesis and vaccination. Compend Contin Educ Pract Vet 1997;19:125-133.
2. Mann FA, Boon GD, Wagner-Mann CC, et al. Ionized and total magnesium concentrations in blood from dogs with naturally acquired parvoviral enteritis. J Am Vet Med Assoc 1998;212:1398-1401.
3. Glickman LT, Domanski LM, Patronek GJ, Visintainer F. Breed-related risk factors for canine parvovirus enteritis. J Am Vet Med Assoc 1985;187:589-594.
4. Otto CM, Drobatz K, Soter C. Endotoxemia and tumor necrosis factor in clinical canine parvoviral enteritis. J Vet Intern Med 1997;11:65-70.
5. Kariuki Njenga M, Nyaga PN, Buoro IBJ, Gathumbi PK. Effectiveness of fluids and antibiotics as supportive therapy of canine parvovirus-2 enteritis in puppies. Bull Anim Health Prod Afr 1990;38:379-389.
6. Dimmilt R. Clinical experience with cross-protective anti-endotoxin antiserum in dogs with parvoviral enteritis. Canine Pract 1991;16:23-26.
7. Rewerts JM, McCaw DL, Cohn LA, et al. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 1998;213:991-992.
8. Krakowka S, Olsen RG, Axhelm MS, et al. Canine parvovirus infection potentiates canine distemper encephalitis attributable to modified live-virus vaccine. J Am Vet Med Assoc 1982;180:137-139.
9. Turk J, Miller M, Brown T, et al. Coliform septicemia and pulmonary disease associated with canine parvoviral enteritis: 88 cases (1987-1988). J Am Vet Med Assoc 1990;196:771-773.
10. Isogai E, Isogai H, Onuma M, et al. Escherichia coli associated endotoxemia in dogs with parvovirus infection. Nippon Juigaku Zasshi 1989;51:597-606.
11. Tracey KJ, Lowry SF, Fahey TD, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987;164:415-422.
12. Stegelmeier BL, Botoms GD, Denicola DB, Reed WM. Effects of flunixin meglumine in dogs following experimentally induced endotoxemia. Cornell Vet 1988;78:221-230.
13. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997;84:920-935.
14. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol 1998;64:14-18.
15. Horwitz AH, Leigh SD, Abrahamson S, et al. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. Protein Expr Purif 1996;8:28-40.